TG Therapeutics

J.P. Morgan 39th Annual Healthcare Conference

January 2021

Forward Looking Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects", "plans", "believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause TG Therapeutics' actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, drug development, and commercialization and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and TG Therapeutics undertakes no obligation to update these statements, except as required by law.

Fearless Pursuit of Innovative Solutions for Patients



Fiercely Focused on B-Cell Diseases

Pipeline of medicines with complementary mechanisms

MEDICINE	MECHANISM OF ACTION	STAGE OF DEVELOPMENT
Umbralisib	PI3Kδ/CK1ε	NDA Filed – MZL/FL
Ublituximab	Anti-CD20	BLA Initiated – U2 CLL Positive Ph3 MS Study
TG-1701	BTKi	Phase 1 (Monotherapy & combo w/ U2)
TG-1801	Anti-CD47/CD19	Phase 1
Cosibelimab (TG-1501)	Anti-PD-L1	Phase 1b

U2

2020: Transformational Year



Positioned for Explosive Growth 2021+



TG Therapeutics

Umbralisib:

Investigational novel inhibitor of PI3k-delta & CK1-epsilon

- **Highly selective to the PI3k-delta isoform with unique inhibition of CK1-epsilon**
- **Pharmacologically distinct from commercially available PI3k inhibitors**
- **Highly active with a favorable safety profile in clinical trials across multiple B-cell malignancies**
- **Oral once daily dosing**

Umbralisib



Target Q1/Q2 2021 potential FDA approvals: monotherapy in R/R MZL/FL

Target mid-2021 BLA/sNDA submission of U2 in CLL

Umbralisib Demonstrated Clinically Meaningful Benefit

UNITY-NHL Pivotal Data

UNITY NHL
TG THERAPEUTICS
UMBRALISIB +/- UBLITUXIMAB
PREVIOUSLY TREATED NHL PATIENTS

- Durable single agent responses across R/R iNHLs
  - No MZL Complete Responses have progressed
- Manageable safety profile, with low incidence of immune mediated toxicities and AE related discontinuations
- NDA accepted by the US FDA
  - MZL PDUFA goal date 2/15/21
  - FL PDUFA goal date 6/15/21

Independent Review Committee (IRC) Assessed Overall Response Rates (ORR)



Zinzani P, et. al., ASH, December 2020

MZL patients were relapsed/refractory to ≥1 prior lines of treatment, including an anti-CD20.
FL patients were relapsed or refractory to ≥2 prior lines, including an anti-CD20 and an alkylating agent
R/R: relapsed/refractory; MZL: marginal zone lymphoma; FL: follicular lymphoma; SLL: small lymphocytic lymphoma; PDUFA: prescription drug user fee act; AE: adverse event; NDA: new drug application

Most Patients Saw A Reduction in Disease Burden with Umbralisib Monotherapy



Zinzani P, et. al., ASH, December 2020

FL: follicular lymphoma; IRC: independent review committee; MZL: marginal zone lymphoma; SLL: small lymphocytic lymphoma; SPD: sum product diameters. DCR: Disease Control Rate Note: Waterfall plot includes all patients with an evaluable post-baseline scan (N=198).

Umbralisib Exhibits Distinct Safety Profile

Extended median follow-up of 27+ months

LOW DISCONTINUATIONS DUE TO AEs

- Discontinuations due to ALT/AST elevations were limited at 2.9%
- Grade 3 diarrhea led to discontinuation of only 2.9% of patients
- 15% discontinuation rate due to AEs observed across patients with MZL, FL and SLL

LIMITED GR 3/4 AEs OF SPECIAL INTEREST

- Opportunistic infections: n=7 (3.4%)
- Rash: n=4 (1.9%)
- Pneumonitis: n=2 (1.0%)
- Non-infectious colitis occurred in 4 patients (1.9%), of which 3 resolved and remained on umbralisib

Zinzani P, et. al., ASH, December 2020

AE: adverse event; ALT: alanine aminotransferase; AST: aspartate aminotransferase. [a]Infectious colitis included 1 case of clostridium difficile colitis. *Includes multiple MedDRA terms.

MZL/FL are Chronic Incurable Diseases[1]

No standard of care after 1st relapse as current options are sub-optimal[2]

of Annually Treated Patients in US[3]



~10,000-12,000 patients estimated in potential labeled indications for umbralisib annually[3]

(1) Denlinger NM, et al. *Cancer Manag Res* 2018 ; (2) ZS Associates ATU, 2020; (3) Putnam Associates, 2019 and Internal Estimates

Commercialization Team Ready for Launch:

PDUFA Feb. 15 (MZL) and June 15, 2021 (FL)

Experienced Team

- ✓ Leadership team launched 5 hematology brands in the last 2 years
- ✓ Sales team with deep expertise:
  - ✓ Average ~20 years hematology experience
  - ✓ Average ~14 years lymphoma experience
- ✓ Extensive relationships with key cancer centers and top KOLs

Full Commercialization Infrastructure

- ✓ COVID ready: Virtual platform and multi-channel capabilities developed
- ✓ Market Access team hired and engaging top payers
- ✓ MSLs hired and supporting scientific engagement
- ✓ Sales force hired

Ublituximab:

Investigational next generation anti-CD20 monoclonal antibody

- **Glycoengineered for enhanced potency**
- **Demonstrated activity in rituximab refractory patients[1]**
- **Shorter infusion time than approved anti-CD20's**
- **2,100+ patients treated with ublituximab, including 3 randomized phase 3 trials**

Target mid 2021 BLA/sNDA submission of U2 in CLL

Positive MS Ph3 Topline Data – Full Presentation 1H 2021

TG Therapeutics

[1]*O'Connor et al, BJH 2016*

Umbralisib+Ublituximab (U2) Trial Met Primary Endpoint

UNITY-CLL Phase 3 Data

- Trial enrolled TN (57%) & R/R CLL patients and compared U2 to Obinutuzumab + Chlorambucil (O+Chl) (n=421)
- First inhibitor of PI3K to successfully treat front-line patients
- Conducted under SPA with the FDA
- Rolling BLA submission initiated in December 2020, full submission targeted for Mid-2021

Met the primary endpoint of

IMPROVED PROGRESSION-FREE SURVIVAL (PFS)

(p<.0001)

Study stopped early for

SUPERIOR EFFICACY

observed at the interim analysis

Gribben J, et. al, ASH 2020

SPA, special protocol assessment; TN, treatment naive; R/R, relapsed and refractory.

Significantly Prolonged Progression-Free Survival

ITT Population (TN & R/R CLL)



CI: confidence interval; HR: hazard ratio; IRC: independent review committee; ITT: intent to treat; O+Chl: obinutuzumab + chlorambucil; PFS: progression-free survival; U2: umbralisib + ublituximab

Gribben J, et. al, ASH 2020

Significantly Prolonged Progression-Free Survival

Treatment Naive Population



CI: confidence interval; HR: hazard ratio; IRC: independent review committee;
O+Chl: obinutuzumab + chlorambucil; PFS: progression-free survival; U2: umbralisib + ublituximab

Gribben J, et. al, ASH 2020

Differentiated Safety Profile of U2 in CLL

Safety consistent across treatment naïve and previously treated CLL

ALL CAUSALITY GRADE 3-4 AEs			
AEs, n (%)	**O + Chl** *Treatment Naïve & Previously Treated* N=200	**U2** *Treatment Naïve* N=116	**U2** *Previously Treated* N=90
Diarrhea	5 (3)	16 (13.8)	9 (10.0)
Nausea	2 (1)	1 (0.9)	2 (2.2)
Infusion related reaction	7 (4)	1 (0.9)	3 (3.3)
Fatigue	6 (3)	4 (3.4)	0
Neutropenia	70 (35)	28 (24.1)	36 (40.0)
Cough	0	0	0
Headache	1 (0.5)	0	1 (1.1)
Pyrexia	2 (1)	1 (0.9)	0
Chills	1 (0.5)	1 (0.9)	0
Upper respiratory tract infection	2 (1)	0	0
Dizziness	26 (13)	2 (1.7)	0

Gribben J, et. al, ASH 2020

TG Therapeutics

Safety was assessed in all patients who received 1 dose of treatment.
U2: umbralisib + ublituximab; CLL: chronic lymphocytic leukemia; AE: adverse event; O+Chl: obinutuzumab + chlorambucil

Global CLL Market Estimated to exceed $10B by 2025[1]

185,000 Americans living with CLL[2]; ~40,000 seeking Treatment Annually[3]

***Current Opportunity*—Potential for U2 to Address Significant Unmet Need in CLL**

- **Not Appropriate/Ineligible for BTKi Patients**
  - ~20% of treatment naive patients are poor candidates for BTKi therapy[4]
- **BTKi-Exposed Patients**
  - Large post-BTKi market with >100,000 patients previously treated[5]
  - ~40% discontinue BTKi due to tolerability or progression at median 17 months[6]

***Future Opportunity*—Potential for Addition of U2 to Standard of Care to Improve Outcomes**

- U2 plus venetoclax and U2 plus BTKi studies underway

(1) Evaluate Pharma; (2) SEER Cancer Stat Facts, 2020; (3) Putnam Associates; (4) ZS Associates ATU, 2020; (5) Internal Market Research; (6) Mato A, et al., Haematologica 2018

U2 + Venetoclax Promising Phase 1 Early Data

Phase 2b ULTRA-V Study Currently Enrolling

Phase 1 ASH 20 Data Update

Treatment well tolerated; AEs consistent with single agent profiles



At Cycle 3:
-**64%** ORR in BTK-ref
-74% for all patients with prior BTKi

Barr P, et. al, ASH 2020

ULTRA-V
U2-V IN CLL

ENROLLING:
- R/R CLL (n=~60)
- BTK Refractory CLL (N=~30)
- Front Line CLL (n=~60)

ENROLLMENT COMPLETION TARGET:
- Q1 2021

PRIMARY ENDPOINT:
- ORR & CR at 12m

TG Therapeutics

Cycle 3 & 7 Assessments were by CT only without BM, therefore CR could not be assessed
*1 BM sample was not analyzed, N=26

BTKi Combination Data

		R/R CLL (N=21)
Umbralisib + Ibrutinib *Davids et. al., EHA 2020*	ORR	95%
	CR	29%

		R/R CLL (N=22)	R/R MZL (N=3)
U2 + Ibrutinib *Nastoupil et. al., LANCET 2.1.2019*	ORR	100%	100%
	CR	36%	33%

		1701 + U2 R/R CLL (N=3)	1701 + U2 R/R MZL (N=2)	1701 200mg R/R CLL (N=20)
TG-1701 +/- U2 *Cheah et.al., ASH 2020*	ORR	100%	100%	95%
	CR		50%	

BTKi = bruton's tyrosine kinase inhibitor; R/R All Pts = CLL, WM, FL, MZL & DLBCL*

Ublituximab Demonstrated Unprecedented ARR

<0.10 ARR in each of the studies based on topline results

ULTIMATE I&II
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB
PHASE 3 TRIALS IN MS

- 1,094 RMS patients enrolled across 10 countries randomized 1:1 to ublituximab or teriflunomide
- Conducted under SPA with the FDA
- Full data presentation expected in 1H 2021
- BLA submission target Mid-2021

ULTIMATE I & II Phase 3 Topline Results

<0.10 ARR

Lowest reported in a Phase 3

p<0.005

~60% AND ~50%

relative reduction in ARR over teriflunomide observed in ULTIMATE I & II, respectively

SPA: special protocol assessment; FDA: Food & Drug Administration; RMS: Relapsing Forms of Multiple Sclerosis

Positive Supportive Phase 2 Data in RMS

- **Annualized Relapse Rate (ARR) of 0.07 was observed with 93% of subjects relapse free at Week 48 (n=48)**
- Median 99% B cell depletion observed at Week 4,maintained at Week 24 and Week 48
- 100% reduction in T1 Gd-enhancing lesions (p=0.003)
- 93% of patients did not experience 24 week confirmed disability progression (CDP)
- 74% of patients achieved clinical and MRI outcomes consistent with NEDA



This is one study participant's MRI; individual results vary.

NEDA: No evidence of Disease Activity

Fox E et al., ECTRIMS 2018

Significant Market Opportunity For Ublituximab in MS



- ~1M Patients Living with MS in the U.S.[1]
- Rapidly growing market: $20B U.S. market growing to $28B by 2025[2]
- Anti-CD20 utilization in MS expanding steadily and expected to grow to >$10+B by 2025[3]
- Multiple $1B+ Treatment Options Coexist in U.S. Market
- ~5,000 Physicians Treat ~80% of the patients

(1) National Multiple Sclerosis Society. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed January 2021.; (2) Datamonitor MS Disease Coverage; (3) Evaluate Pharma MS Indication Profile, October 2020; Chart Note: Figures reflect 2019 global sales in billions; Chart Source: Evaluate Pharma MS Indication Profile, October 2020

Ublituximab Offers Potentially Best-In Class Profile

Ublituximab for MS

CLINICAL

Only anti-CD20 to demonstrate ARR <0.10 in a Phase 3

CONVENIENCE

1 hour infusion every 6 months (after 1st infusion)

ACCESS

Plan to strategically price to optimize patient access

Positioned to Achieve Multiple Projected Milestones in 2021

$600m proforma cash as of YE 2020

REGULATORY	COMMERCIAL	CLINICAL & PIPELINE
Umbralisib R/R MZL PDUFA – 2/15	Execute successful umbralisib launch for R/R MZL and FL	Completion of ULTRA-V Ph2B enrollment – Q1
Umbralisib R/R FL PDUFA – 6/15	Prepare for CLL and MS launches	ULTIMATE I&II full data – 1H
Completion of U2 CLL BLA/sNDA submission – 1H		Additional triplet data
Ublituximab MS BLA submission – Mid-year		Advance early-stage pipeline

TG Therapeutics

NASDAQ: TGTX